Drug Trial News

RSS

The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women

Antimicrobial treatments for bacterial vaginosis (BV) are effective, but taking lactobacillus tablets alongside metronidazole antibiotic therapy increases effectiveness over taking this antibiotic alone, according to a Cochrane Systematic Review. The researchers also concluded that intravaginal lactobacillus was as effective as oral metronidazole, although they did note unexplained drop-outs from the trials.

7 Jul 2009

Artemisinin-based combination therapy for treating uncomplicated malaria

Current combination malaria therapies recommended by the World Health Organisation (WHO) provide adequate treatment for mild malaria, according to a Cochrane Systematic Review of the evidence. However, selected trials had high failure rates for some combinations and evidence for the effectiveness of anti-malarial therapies is lacking in some vulnerable groups.

7 Jul 2009

PATRICIA trial shows HPV vaccine effective in prevention of cervical lesions

The final analysis of the PATRICIA study shows that the HPV-16/18 AS04-adjuvanted vaccine (GlaxoSmithKline) has high efficacy against the precancerous cervical lesions that can eventually lead to cervical cancer.

6 Jul 2009

Antidepressants aid electroconvulsive therapy in treating severe depression

Combining antidepressant drugs with electroconvulsive therapy (ECT) does a better job of reducing symptoms of severe depression and causes less memory loss than using ECT alone, according to a new study by researchers at Wake Forest University School of Medicine and colleagues.

6 Jul 2009

Question marks on credibility of some published clinical trials

Randomised Controlled Trials (RCTs) are considered the 'gold standard' research method for assessing new medical treatments. But research published in BioMed Central's open access journal Trials shows that the design of a remarkable 93 percent of 2235 so-called RCTs published in some Chinese medical journals during 1994 to 2005 was flawed, casting doubt on the reliability of research that is likely to influence medical decision-makers.

2 Jul 2009

Moxidectin being tested for onchocerciasis

A clinical trial is being launched in three African countries of a drug that could eliminate onchocerciasis, or river blindness, one of the leading infectious causes of blindness across Africa. The drug, moxidectin, is being investigated for its potential to kill or sterilize the adult worms of Onchocerca volvulus, which cause onchocerciasis.

1 Jul 2009

Golimumab shows promise for rheumatoid arthritis

Golimumab, a new tumour necrosis factor-α (TNF-α) inhibitor reduces the signs and symptoms of rheumatoid arthritis in patients who have previously received any other TNF-α inhibitor, and might be a good option for patients who have inadequate responses to one or two other TNF-α inhibitors, finds an Article published Online first and in this week's edition of The Lancet.

28 Jun 2009

Inhaled growth hormone safe for children deficient in this key protein

A multi-center clinical trial led by a Riley Hospital for Children endocrinologist has found that inhaled growth hormone (GH) is well tolerated by children with GH deficiency and that this easy-to-use method can, over a one-week period, safely deliver GH to the blood stream. In addition to having implications for those who need GH, this first pediatric study of administering it through the lungs may also help researchers interested in using this convenient method for effectively delivering other types of medications to children.

28 Jun 2009

Clinical trial raises hope for Australian diabetics to be insulin free

A clinical trial for a new treatment for type 1 diabetes which potentially eliminates the need for daily insulin injections will commence in New Zealand by Australian company Living Cell Technologies (LCT).

23 Jun 2009

Seattle Genetics starts trial of SGN-35 for anaplastic large cell lymphoma

Seattle Genetics, Inc. (NASDAQ:SGEN), has announced that it has initiated a phase II clinical trial of SGN-35 for patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). SGN-35 is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics’ proprietary technology to empower antibodies by linking them to potent cell-killing drugs.

18 Jun 2009

Antisense Therapeutics trial of ATL1101 in prostate cancer shows promise

Antisense Therapeutics Ltd. (ASX: ANP) has reported further positive results from its collaborative preclinical research studies on the therapeutic potential of ATL1101 in prostate cancer. In experimental models, ATL1101 treatment significantly enhanced the tumor-suppressive effect of the cancer drug Paclitaxel. Paclitaxel is one of a class of drugs known as taxanes.

18 Jun 2009

Globe and Mail examines GlaxoSmithKline's RTS,S malaria vaccine trials in Kenya

The Globe and Mail examines GlaxoSmithKline's RTS,S malaria vaccine trials in Kilifi, Kenya – one of the sites where the experimental vaccine is being tested. "The stories of the mothers of Kilifi open a window on the challenges faced by researchers as they build a trial that will include more than 16,000 babies from 11 sites spread across sub-Saharan Africa," the Globe and Mail reports.

18 Jun 2009

Cholesterol-lowering statin drugs do not lower risk of pneumonia in seniors

Taking popular cholesterol-lowering statin drugs, such as Lipitor (atorvastatin), does not lower the risk of pneumonia. That's the new finding from a study of more than 3,000 Group Health patients published online on June 16 in advance of the British Medical Journal's June 20 print issue.

17 Jun 2009

Trial of new ‘combo’ treatment for hepatitis C

In a multi-center trial led by a Saint Louis University researcher, investigators found that a new combination therapy of daily consensus interferon and ribavirin helps some hepatitis C patients who have not responded to previous treatment.

17 Jun 2009

Topical fluorouracil may improve appearance of aging skin

Topical application of the chemotherapy medication fluorouracil appears to reduce potentially precancerous skin patches and improve the appearance of sun-damaged skin, according to a report in the June issue of Archives of Dermatology.

16 Jun 2009

Pneumococcal vaccine effective in preventing severe pneumonia

A new trial has found that pneumococcal vaccine is effective in preventing severe pneumonia, the leading cause of death among children in developing countries. Co-ordinated by the National Institute for Health and Welfare (THL) between 2000 and 2004, a large scale efficacy trial - first of its kind in Asia - was carried out in the Philippines to investigate the effect of an investigational pneumococcal vaccine.

16 Jun 2009

Antiretroviral therapy earlier yields better clinical outcomes

A clinical trial has demonstrated that HIV-infected adults in a resource-limited setting are more likely to survive if they start antiretroviral therapy (ART) before their immune systems are severely compromised.

9 Jun 2009

Novel diabetes treatment Syncria (albiglutide) improves glucose control and reduces weight

New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.

9 Jun 2009

Botox injections can help overactive bladders sufferers

Botox is well known for its cosmetic uses, but researchers have now found that it can also significantly improve people's quality of life if they suffer from another problem that increases with age, an overactive bladder (OAB).

9 Jun 2009